Harrow, Inc. Debt Instrument, Convertible, Conversion Price
Harrow, Inc. (HROW) had Debt Instrument, Convertible, Conversion Price of $5.90 per share as of 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentConvertibleConversionPrice1 · last filed 2018-03-08
- 2017-12-31: Debt Instrument, Convertible, Conversion Price $5.90.
- 2016-12-31: Debt Instrument, Convertible, Conversion Price $5.90.
- 2016-09-30: Debt Instrument, Convertible, Conversion Price $5.90.
- 2016-06-30: Debt Instrument, Convertible, Conversion Price $5.90.
| Period end | Debt Instrument, Convertible, Conversion Price |
|---|---|
| 2017-12-31 | $5.90 10-K · filed 2018-03-08 |
| 2016-12-31 | $5.90 10-K · filed 2017-03-21 |
| 2016-09-30 | $5.90 10-Q · filed 2016-11-14 |
| 2016-06-30 | $5.90 10-Q · filed 2016-08-15 |
| 2016-03-16 | $5.90 10-K · filed 2018-03-08 |
| 2010-04-05 | $40.00 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |